Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Tissue Regenix Group PLC Announces Results of Safety Study of dCELL Meniscus


Thursday, 14 Feb 2013 02:00am EST 

Tissue Regenix Group PLC (TRX) announced that a pre-clinical study to assess the safety of Tissue Regenix's dCELL meniscus has delivered positive results that pave the way for clinical studies to begin in Europe following regulatory review. The six month study to assess the biocompatibility of the dCELL meniscus involved a standard procedure called a partial meniscectomy where the dCELL meniscus is implanted next to existing tissue. Key findings at the conclusion of the study indicate that the device is safe with no adverse or inflammatory responses related to the device detected. In addition there were signs of cells entering the dCELL meniscus and signs of remodelling (characterised by the appearance of collagen - a key component of healthy tissue), which indicate that the meniscus is successfully integrating with the existing tissue. 

Company Quote

29.375
2.0 +7.14%
17 Apr 2014